Physician profile
Gilbert Smith
NPI 1508235359
$4,194.45
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,117 · 2020: $482 · 2021: $655 · 2022: $786 · 2023: $639 · 2024: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,153.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $924.46 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $681.36 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $663.31 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $481.35 | 2022-2024 | Abilify Asimtufii, Rexulti |
| Corium, LLC | $375.03 | 2021-2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $316.00 | 2020-2023 | Trintellix |
| Astrazeneca Pharmaceuticals Lp | $123.84 | 2023 | Farxiga |
| Vertical Pharmaceuticals, LLC | $98.78 | 2019-2020 | |
| Shire North American Group INC | $96.16 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.42 | 2023-2024 | Caplyta |
| Lundbeck LLC | $86.62 | 2023-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $85.06 | 2022-2023 | Qelbree |
| Alkermes, INC. | $75.97 | 2023 | Lybalvi |
| Abbvie INC. | $58.24 | 2023 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $23.09 | 2024 | Austedo Xr |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $14.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilbert Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.